<DOC>
	<DOCNO>NCT00791557</DOCNO>
	<brief_summary>Subjects must 18- 75 year old history inflammatory bowel disease ( Crohn 's ulcerative colitis ) pyoderma gangrenosum . This 6 month open label study intravenous ( IV ) medication . Visits occur every 2 week initially , every 1-2 month later study .</brief_summary>
	<brief_title>Open Label Study Adults With Pyoderma Gangrenosum Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Must Be ages 1875 Must inflammatory bowel disease moderate severe pyoderma gangrenosum Must never receive Infliximab treatment pyoderma gangrenosum Have previous treatment monoclonal antibody infliximab use treat IBD antibody fragment . Have history serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>